Method development and validation of simultaneous estimation for Amlodipine besylate and Olmesartan medoxomil by UV- VISIBLE spectrophotometric Method

Abstract

The present experiment works on routine initiation and scientific recognization of a typical, exact and meticulous UV-Visible Spectrophotometric process for the synchronous assessment of Amlodipine besylate and Olmesartan medoxomil. The working solutions of Amlodipine and Olmesartan medoxomil were scanned at 240 nanometer and 230 nanometer respectively. The regression strength of Amlodipine besylate and Olmesartan medoxomil over its absorbances were obtained as y = 0.068x-0.2182 and y = 0.067x0.0386 respectively with a correlation coefficient (r2) of 0.9995 for Amlodipine besylate and 0.9992 for Olmesartan medoxomil. The intra-day precision in addition inter-day precision for Amlodipine besylate and its % RSD were obtained as 0.15% and 0.39% individually. The intra-day precision in addition inter-day precision for Olmesartan medoxomil and % RSD were obtained as 0.39% and 0.14%, respectively. The precise amount of tablet formulation were added which holds Alkaline (0.1 N Sodium hydroxide), Acidic (0.1 N Hydrochloric acid) reflux for 3 hours, 3% Oxydol at 50ºC, heat (60ºC), humidity (75 Relative percentage humidity) for 24 hr and after the particular time quantity was dissolved with distilled water, separated using Filter paper. From this stock solution, 5 mL part of the filtrate was isolated and further diluted by distilled water in a 100 mL standard flask (10 µg/mL). The standard solution of two drugs were compared against a label claim.